101 related articles for article (PubMed ID: 28550929)
1. Arrhythmia and Clinical Cardiac Findings in Children With Anderson-Fabry Disease.
Wilson HC; Hopkin RJ; Madueme PC; Czosek RJ; Bailey LA; Taylor MD; Jefferies JL
Am J Cardiol; 2017 Jul; 120(2):251-255. PubMed ID: 28550929
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease.
Deva DP; Hanneman K; Li Q; Ng MY; Wasim S; Morel C; Iwanochko RM; Thavendiranathan P; Crean AM
J Cardiovasc Magn Reson; 2016 Mar; 18():14. PubMed ID: 27036375
[TBL] [Abstract][Full Text] [Related]
3. Arrhythmogenesis in Fabry Disease.
Roy A; Cumberland MJ; O'Shea C; Holmes A; Kalla M; Gehmlich K; Geberhiwot T; Steeds RP
Curr Cardiol Rep; 2024 Jun; 26(6):545-560. PubMed ID: 38607539
[TBL] [Abstract][Full Text] [Related]
4. Smoking Accelerates Atrioventricular Conduction in Humans Concordant with Increased Dopamine Release.
Irfan AB; Arab C; DeFilippis AP; Lorkiewicz P; Keith RJ; Xie Z; Bhatnagar A; Carll AP
Cardiovasc Toxicol; 2021 Feb; 21(2):169-178. PubMed ID: 33043409
[TBL] [Abstract][Full Text] [Related]
5. Anderson-Fabry disease management: role of the cardiologist.
Pieroni M; Namdar M; Olivotto I; Desnick RJ
Eur Heart J; 2024 Apr; 45(16):1395-1409. PubMed ID: 38486361
[TBL] [Abstract][Full Text] [Related]
6. Anderson-Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement.
Iorio A; Lucà F; Pozzi A; Rao CM; Chimenti C; Di Fusco SA; Rossini R; Caretta G; Cornara S; Giubilato S; Di Matteo I; Di Nora C; Pilleri A; Gelsomino S; Ceravolo R; Riccio C; Grimaldi M; Colivicchi F; Oliva F; Gulizia MM; ; The Cardiac Rare Diseases Working Group Associazione Nazionale Medici Cardiologi Ospedalieri Anmco
Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38248084
[TBL] [Abstract][Full Text] [Related]
7. Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies.
Averbuch T; White JA; Fine NM
Front Cardiovasc Med; 2023; 10():1152568. PubMed ID: 37332587
[TBL] [Abstract][Full Text] [Related]
8. When Do Smartwatch Heart Rate Concerns in Children Indicate Arrhythmia?
Dechert BE; LaPage MJ
J Pediatr; 2023 Dec; 263():113717. PubMed ID: 37660972
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Fabry Disease and Outcomes in Young Canadian Patients With Cryptogenic Ischemic Cerebrovascular Events.
Lanthier S; Saposnik G; Lebovic G; Pope K; Selchen D; Moore DF;
Stroke; 2017 Jul; 48(7):1766-1772. PubMed ID: 28596458
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors.
Arends M; Biegstraaten M; Hughes DA; Mehta A; Elliott PM; Oder D; Watkinson OT; Vaz FM; van Kuilenburg ABP; Wanner C; Hollak CEM
PLoS One; 2017; 12(8):e0182379. PubMed ID: 28763515
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for Diagnosing and Staging of Fabry Disease.
Kramer J; Weidemann F
Curr Med Chem; 2018; 25(13):1530-1537. PubMed ID: 28618999
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease and its cardiac involvement.
Kubo T
J Gen Fam Med; 2017 Oct; 18(5):225-229. PubMed ID: 29264031
[TBL] [Abstract][Full Text] [Related]
13. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice.
Baig S; Edward NC; Kotecha D; Liu B; Nordin S; Kozor R; Moon JC; Geberhiwot T; Steeds RP
Europace; 2018 Sep; 20(FI2):f153-f161. PubMed ID: 29045633
[TBL] [Abstract][Full Text] [Related]
14. [Fabry disease: An overlooked diagnosis in adult cardiac patients].
Kayıkçıoğlu M; Şimşek E; Kalkan Uçar S; Bayraktaroğlu S; Onay H; Sözmen E; Çoker M
Turk Kardiyol Dern Ars; 2017 Sep; 45(6):549-555. PubMed ID: 28902648
[TBL] [Abstract][Full Text] [Related]
15. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
[TBL] [Abstract][Full Text] [Related]
16. Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy.
Yogasundaram H; Kim D; Oudit O; Thompson RB; Weidemann F; Oudit GY
Can J Cardiol; 2017 Jul; 33(7):883-897. PubMed ID: 28668140
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
18. Fabry heterozygote mimicking multiple sclerosis.
Yau WY; Fabis-Pedrini MJ; Kermode AG
BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28576916
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
20. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34
Huang J; Khan A; Au BC; Barber DL; López-Vásquez L; Prokopishyn NL; Boutin M; Rothe M; Rip JW; Abaoui M; Nagree MS; Dworski S; Schambach A; Keating A; West ML; Klassen J; Turner PV; Sirrs S; Rupar CA; Auray-Blais C; Foley R; Medin JA
Mol Ther Methods Clin Dev; 2017 Jun; 5():241-258. PubMed ID: 28603745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
